title: Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.
abstract: Recurrent episodes of hepatic encephalopathy (HE) frequently occur in surgically shunted cirrhotic patients. The prevention of these episodes is based mainly on the long-term use of lactulose. Recently, lactitol, a nonabsorbable disaccharide similar to lactulose, has been proposed as an alternative in the management of HE. It has the advantage of being better tolerated and producing a more predictable catharsis. The effects of the two agents were compared in a controlled randomized study lasting six months involving 31 cirrhotic patients with portal-systemic shunt, of whom 40% experienced HE. The PSE index (mental state, EEG, asterixis, Raitan test, and ammonia) was assessed in each patient on entry to the study and every three months during treatment. Episodes of HE, side effects, and the patients' comments on efficacy, tolerability, and palatability were recorded. The dose required to induce two bowel movements per day was 48 +/- 25 ml of lactulose syrup and 36 +/- 7 g of lactitol. During the study, the number of patients who had an episode of HE and the PSE index was similar in both groups. The patients judged lactitol better from the point of view of palatability. Meteorism and flatulence, experienced by patients treated with lactulose, was not reported by the lactitol group. We concluded that lactitol is as effective as lactulose in the long-term prevention of episodes of HE in cirrhotics with portal-systemic shunt and may be better tolerated.
authors.affiliation: Department of Internal Medicine, University of l'Aquila, Italy.
authors.forename: O
authors.initials: O
authors.lastname: Riggio
authors.forename: G
authors.initials: G
authors.lastname: Balducci
authors.forename: F
authors.initials: F
authors.lastname: Ariosto
authors.forename: M
authors.initials: M
authors.lastname: Merli
authors.forename: U
authors.initials: U
authors.lastname: Pieche
authors.forename: G
authors.initials: G
authors.lastname: Pinto
authors.forename: S
authors.initials: S
authors.lastname: Tremiterra
authors.forename: V
authors.initials: V
authors.lastname: Ziparo
authors.forename: L
authors.initials: L
authors.lastname: Capocaccia
mesh_terms: D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006501:Hepatic Encephalopathy / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007792:Lactulose / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011170:Portasystemic Shunt, Surgical / Q000009:adverse effects; D011897:Random Allocation; D012008:Recurrence; D013402:Sugar Alcohols / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000596:Amino Acids; D013402:Sugar Alcohols; D007792:Lactulose; C014635:lactitol